Trials / Active Not Recruiting
Active Not RecruitingNCT06054113
Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
An Open-label, Multicenter, Phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics (PK) of Blinatumomab in Chinese Pediatric Subjects With Relapsed or Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 1 Month – 204 Months
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the efficacy of blinatumomab.
Conditions
- B Precursor Acute Lymphoblastic Leukemia
- Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Blinatumomab | Administered via CIVI |
Timeline
- Start date
- 2024-07-23
- Primary completion
- 2026-01-05
- Completion
- 2027-10-14
- First posted
- 2023-09-26
- Last updated
- 2026-01-27
Locations
7 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06054113. Inclusion in this directory is not an endorsement.